LLY's Mounjaro and Zepbound drove 56% of revenues in 2025 as obesity demand surged, with new launches and Medicare access set to fuel growth.

New trial data show tirzepatide outperforms a GLP 1 combo in weight loss, reshaping obesity drug competition, and treatment ...

After its next-generation obesity asset CagriSema lost a head-to-head matchup with Eli Lilly’s Zepbound, Novo Nordisk is ...

The Danish drugmaker is collaborating with Vivtex, cofounded by billionaire Robert Langer, to quickly iterate oral versions ...

During the State of the Union on Tuesday night, President Donald Trump pointed to lower drug prices as an achievement of the ...

U.S. childhood and teen obesity rates have reached record-highs while adult obesity rates may be slowing, according to two ...

After finding itself some unwanted attention this week, Novo Nordisk (NYSE:NVO) has dropped 22% in the past week and 56% over ...

Despite being first to launch a GLP-1 drug for weight loss, Novo's market share has eroded, and the company now only captures about 40% of the market.

Eli Lilly and Company (NYSE:LLY) is included among the Goldman Sachs Dividend Stocks: Top 14 Stock Picks. On February 24, ...

Judge Karen Marston of the Eastern District of Pennsylvania issued the Order on February 23, 2026 Appointing Jason Goldstein to Co-Chair of the Plaintiffs' Executive Committee and Federal-State Court ...